Mycophenolic acid (MPA) is an immunosuppressive drug that is primarily used in combination with cyclosporine A, tacrolimus or corticosteroids for the purpose of preventing organ rejection following transplantation. The large interindividual pharmacokinetic variability and the narrow therapeutic window, result in the need for therapeutic drug monitoring, which allows for the optimization of therapy and consequently more favorable treatment outcomes. The challenge with MPA quantification is the interference of its metabolite mycophenolic acid glucuronide (MPAG), which requires the development of appropriate analytical determination methods. Liquid chromatography coupled with tandem mass spectrometry represents the gold standard method for quantification of MPA and MPAG due to its selectivity, sensitivity and the possibility of determining multiple analytes simultaneously. The purpose of this master's thesis was to validate the method for the determination of MPA and its metabolic product – MPAG. We validated the precision, accuracy, linearity, lower limit of determination, selectivity, carryover between samples, ion ratios and matrix effect, using the recommendations and guidelines of the Institute for Clinical and Laboratory Standards to verify the adequacy of these parameters. By analyzing three concentration levels, we confirmed the adequate repeatability and intra-laboratory precision of the method (CV ≤ 15 %), and the adequate accuracy was confirmed by determining the concentrations of calibration and control samples and comparing them with the nominal value specified by the manufacturer (total analytical error tolerance interval ≤ 20 % of nominal value). We evaluated the lower limit of determination (MPA = 0,12 mg/L, MPAG = 6,3 mg/L) and confirmed linearity for both analytes over the entire tested range (MPA = 0,12–47,40 mg/L, MPAG = 2,5–393,0 mg/L). We also confirmed the appropriate selectivity of the method, demonstrating that hemolysis, ictericity, lipemia and other components of the sample do not affect the result. No relevant carry-over was detected for MPAG. However, a concentration-dependent carry-over was observed for MPA. Consequently, any sample analyzed immediately after a sample with a concentration > 10 mg/L will be re-analyzed. We also determined the matrix effect, which ranged from 82,6 to 113,8 %. The high recovery confirmed the adequacy of sample preparation, and the efficiency calculation, which combines both matrix and recovery effects, yielded high values that indicate there is no significant analyte loss during sample preparation and analysis. With this successful validation of the method, we confirm its suitability for use in clinical practice.
|